ODI Pharma is a producer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are made through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. Operations are found within the European market, with the headquarters in Stockholm.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Volker Wiederrich | 38,43 | 38,43 | 2025-12-23 |
| Niclas Kappelin | 29,02 | 29,02 | 2025-12-23 |
| Derek Simmross | 23,23 | 23,23 | 2025-12-23 |
| Jan-Mark Edewaard | 1,92 | 1,92 | 2026-01-08 |
| Andreas Klahr | 0,37 | 0,37 | 2025-12-23 |
| Tomi Kalevi Heikkinen | 0,27 | 0,27 | 2025-12-23 |
| Carl Fredrik Christoffer Clementson | 0,19 | 0,19 | 2025-12-23 |
| Avanza Pension | 0,18 | 0,18 | 2025-12-23 |
| Malena Karanovic | 0,17 | 0,17 | 2025-12-23 |
| Nordnet Pensionsförsäkring | 0,13 | 0,13 | 2025-12-23 |
2026-02-26 Interim Report 2026-Q2
2026-05-28 Interim Report 2026-Q3
2026-08-27 Year End Report 2026
